Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Advertisement
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
A new study aimed to confirm the possible synergy between loncastuximab and rituximab.
A phase 2 study presented at ASH 2024 hint at a chemo-free option for elderly patients with MCL
Treatment choice significantly influences outcomes in patients with mantle cell lymphoma.
Patients with follicular lymphoma and early progression are a distinctly vulnerable population who need further study.
Odronextamab showed durable response rates and an acceptable safety profile in the phase I ELM-1 and phase II ELM-2 trials.
The approval was based on results from the EPCORE® NHL-1 trial, in which epcoritamab achieved an ORR of 82%.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.